[Form 4] Ocuphire Pharma, Inc. Common Stock Insider Trading Activity

Rhea-AI Filing Summary

Opus Genetics, Inc. director Gallagher Cam reported a purchase of 869,565 shares of the issuer's common stock on 08/25/2025 at a price of $1.15 per share. After the transaction the reporting person beneficially owned 1,810,430 shares. The Form 4 was submitted by power of attorney on 08/27/2025.

Positive

• Material insider purchase: Acquisition of 869,565 common shares at $1.15 indicates a meaningful increase in insider exposure.
• Increased beneficial ownership: Resulting ownership of 1,810,430 shares provides clearer alignment between director and shareholders.
• Timely disclosure: Form 4 filed and signed via power of attorney within two days of the transaction date.

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider purchase increases director stake materially, signaling personal investment in the company.

The Form 4 shows a non-derivative acquisition of 869,565 common shares at $1.15 each, raising the reporting person's beneficial holding to 1,810,430 shares. For investors, an insider purchase of this size is a relevant signal of the director's confidence, although the filing contains no explanation of financing or intent. The disclosure is routine and compliant with Section 16 reporting requirements.

Corporate Governance Expert

TL;DR: Transaction properly reported; documentation signed via power of attorney.

The Form 4 is complete for the non-derivative acquisition and includes a signature executed by power of attorney. There are no amendments or derivative transactions reported. The filing provides the necessary details for regulatory transparency but does not include any explanatory notes about the purpose of the purchase.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gallagher Cam

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NC 27713

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2025		A		869,565	A	$1.15	1,810,430	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Amy Rabourn, by Power of Attorney	08/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 and what was reported?

Director Gallagher Cam reported a purchase of 869,565 common shares on 08/25/2025 at $1.15 per share, increasing beneficial ownership to 1,810,430 shares.

What issuer is identified in the Form 4?

The Form 4 lists the issuer as Opus Genetics, Inc. [ IRD ].

When was the Form 4 signed and by whom?

The filing was signed on 08/27/2025 by /s/ Amy Rabourn, by Power of Attorney.

Was the transaction in non-derivative or derivative securities?

The reported transaction was in non-derivative common stock; no derivative securities were reported on the form.

Does the Form 4 disclose any disposition or derivative activity?

No. The filing shows only an acquisition (A) of common stock and does not report any dispositions or derivative transactions.